Cellular Biomedicine Group, Inc. develops cell therapies for the treatment of certain degenerative diseases. The Company offers developmental stem cell, progenitor cell, and immune cell projects. The Company has acquired, transferred, commercialized and advanced research and human treatment experience in progenitor cells and cancer cell technology. The Company is developing biomedicine based on tissue-derived progenitor cells, embryonic stem (ES) cells and cancer-specific dendritic cells. It considers these cell types as viable options for cell-based therapies to apply to a variety of medical indications.